NewYork-Presbyterian Hospital/Columbia University Medical Center is the only center in the New York City area where the therapy is currently available.
Patients enrolled in the multicenter CUPID trial (Calcium Up-Regulation by Percutaneous Administration of Gene Therapy in Cardiac Disease) will undergo a minimally invasive cardiac catheterization procedure that will introduce a specially engineered gene that stimulates production of an enzyme necessary for the heart to pump more efficiently.
"This new therapy seeks to replenish the levels of this enzyme by introducing the gene for SERCA2a, which is depressed in these patients. If proven effective, this approach could be an alternative to heart transplant for patients without any other options," says Dr. Donna Mancini, the study's principal investigator at NewYork-Presbyterian Hospital/Columbia University Medical Center, where she is medical director of cardiac transplantation. She also is professor of medicine at Columbia University College of Physicians and Surgeons.
Gene therapy is a technique for correcting defective genes responsible for disease development by inserting genes into a patient's cells and tissues. In most gene therapy studies, a "normal" gene is inserted into the genome to replace an "abnormal" disease-causing gene. A carrier molecule called a vector must be used to deliver the therapeutic gene to the patient's target cells. Currently, the most common vector is a non-pathogenic virus most people have been exposed to in adolescence that has been genetically altered to carry normal human DNA.
More than five million people in the U.S. have heart failure. Patients with severe form of the disease have trouble breathing because the heart cannot pump fluid out of their lungs. Seventy percent die of the disease within 10 years, and the five-year survival rate is less than 50 percent. Heart failure is the only cardiovascular disease whose incidence has been increasing rather than decreasing.
Source: New York- Presbyterian Hospital/Columbia University Medical Center
Related stories:
Medicine tailored to your genome, not your race: Venter
Personalised, genome-based health care could help prevent hundreds of thousands of deaths caused each year by adverse drug reactions, genetics pioneer Craig Venter said Tuesday.
Blood pressure response to daily stress provides clues for better hypertension treatment
How the body regulates blood pressure in response to daily stress is the focus of a study geared toward helping people whose pressure is out of control.
Improved estrogen reception may sharpen fuzzy memory
Estrogen treatments may sharpen mental performance in women with certain medical conditions, but University of Florida researchers suggest that recharging a naturally occurring estrogen receptor in the brain may also clear cognitive cobwebs.
Middle Eastern families yield intriguing clues to autism
Research involving large Middle Eastern families, sophisticated genetic analysis and groundbreaking neuroscience has implicated a half-dozen new genes in autism. More importantly, it strongly supports the emerging idea that autism stems from disruptions in the brain's ability to form new connections in response to experience – consistent with autism's onset during the first year of life, when many of these connections are normally made.
UC researchers find new ways to regulate genes, reduce heart damage
Researchers at the University of Cincinnati (UC) are looking for ways to reduce or prevent heart damage by starting where the problem often begins: in the genes.
Gene variation may be why some don't respond to cholesterol-lowering drugs
A variation in the way the body processes a single protein may explain why some people don't respond well to drugs that lower "bad" cholesterol, according to a report in
Circulation: Journal of the American Heart Association.
Caution on stem cell therapy
A single organ may contain more than one type of adult stem cell – a discovery that complicates prospects for using the versatile cells to replace damaged tissue as a treatment for disease, according to a new study from the laboratory of geneticist Mario Capecchi, the University of Utah's Nobel Laureate.
Double duty: Loss of protective heart failure protein causes high blood pressure
Scientists at the Center for Translational Medicine at Thomas Jefferson University in Philadelphia have found that a protein that appears to have protective and perhaps healing effects for failing hearts also plays a similar role in high blood pressure. They found lower-than-normal levels of the protein S100A1 in cells that line blood vessel walls in animals with high blood pressure.